Pharmacokinetics of Oral Recombinant Human Parathyroid Hormone [rhPTH(1–31)NH2] in Postmenopausal Women with Osteoporosis

Parathyroid Hormone (1-34)-Coated Microneedle Patch System: Clinical Pharmacokinetics and Pharmacodynamics for Treatment of Osteoporosis

Peter E. Daddona, James A. Matriano, Jaap W. Mandema et al. · Pharmaceutical Research · 2010 · 232 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +14

Effect of an Intermittent Weekly Dose of Human Parathyroid Hormone (1-34) on Osteoporosis: A Randomized Double-Masked Prospective Study Using Three Dose Levels

Tomohiro Fujita, T. Inoue, H Morii et al. · Osteoporosis International · 1999 · 119 citations

Medicine, Endocrinology, Bone Metabolism +12

Pharmacokinetics of Teriparatide (rhPTH[1–34]) and Calcium Pharmacodynamics in Postmenopausal Women with Osteoporosis

Julie Satterwhite, Michael Heathman, Paul D. Miller et al. · Calcified Tissue International · 2010 · 107 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

The Effects of Ronacaleret, a Calcium-Sensing Receptor Antagonist, on Bone Mineral Density and Biochemical Markers of Bone Turnover in Postmenopausal Women with Low Bone Mineral Density

Lorraine A. Fitzpatrick, Christine Dabrowski, Greg Cicconetti et al. · The Journal of Clinical Endocrinology & Metabolism · 2011 · 80 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1–31)NH2] in postmenopausal women with osteoporosis

Kim Henriksen, J.R. Andersen, B.J. Riis et al. · Bone · 2012 · 53 citations

Medicine, Pharmacokinetics, Pharmacology +14